title: A comparison of nicardipine and labetalol for acute hypertension management following stroke.
abstract: OBJECTIVE
  Evaluate the ease of use and tolerability of labetalol (L) and nicardipine (N) for hypertension management in patients with acute stroke.
  
  
  METHODS
  This is a retrospective, non-randomized study. Consecutive adults within 24 h of hospital admission who received intravenous bolus labetalol or nicardipine infusion as first-line antihypertensive therapy were identified. Hemodynamic data were collected through 24 h of therapy.
  
  
  RESULTS
  Ninety patients received either labetalol (N = 64) or nicardipine (N = 26) initially for blood pressure (BP) management. Stroke types were 54% intracerebral hemorrhage (ICH), 22% subarachnoid hemorrhage, and 23% ischemic stroke and were similar between the two drug groups. Baseline patient characteristics and disease severity (APACHE II and GCS) were similar between groups. The average total daily labetalol dose was 40 (10-340) mg and nicardipine infusion was 5 (1-14) mg/h. Initial BP was similar in the two groups. The nicardipine group had less BP variability (N 8.19 vs. L 10.78 mmHg; p = 0.003), fewer dosage adjustments [L 4 (1-17), N 2 (0-5); p < 0.001] and fewer additional antihypertensive agents (L 33%, N 8%; p = 0.013) administered during the 24-h observation period. In patients with ICH, 33% of nicardipine-treated patients achieved target BP within the first 60 min versus 6% of the L group (p = 0.02). Overall, incidence of hypotension (SBP < 90 mmHg) (L 3%; N 0%) and bradycardia (HR < 60 beats per min) (L 20.6%; N 12%) were comparable between the groups.
  
  
  CONCLUSIONS
  Nicardipine offers an alternative to labetalol with similar tolerability and appears to provide a smoother blood pressure control compared to labetalol.
authors.affiliation: Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, 48201, USA.
authors.forename: Xi
authors.initials: X
authors.lastname: Liu-Deryke
authors.forename: James
authors.initials: J
authors.lastname: Janisse
authors.forename: William M
authors.initials: WM
authors.lastname: Coplin
authors.forename: Dennis
authors.initials: D
authors.lastname: Parker
authors.forename: Gregory
authors.initials: G
authors.lastname: Norris
authors.forename: Denise H
authors.initials: DH
authors.lastname: Rhoney
mesh_terms: D018806:APACHE; D000208:Acute Disease; D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001794:Blood Pressure / Q000187:drug effects; D002545:Brain Ischemia / Q000150:complications; D002543:Cerebral Hemorrhage / Q000150:complications; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy*; D007741:Labetalol / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009529:Nicardipine / Q000008:administration & dosage*; D012189:Retrospective Studies; D020521:Stroke / Q000150:complications*; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D009529:Nicardipine; D007741:Labetalol